Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19
Related Experiment Video
Updated: Jul 9, 2025
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
Arantxa Horga1, Daniel R Kuritzkes2, John J Kowalczyk3
1Atea Pharmaceuticals, Boston, MA 02110, USA.
Background:
Bemnifosbuvir, a novel, oral, nonmutagenic, nonteratogenic nucleotide analogue inhibits SARS-CoV-2 replication in vitro.
Materials & Methods:
Adults in hospital settings with moderate COVID-19 were randomized 1:1 bemnifosbuvir/placebo. Study amended to two parts after interim analysis; part B enrollment limited owing to evolving standard of care.
Results:
Although the study ended early and did not meet the primary efficacy end point, bemnifosbuvir was well tolerated and did not contribute to all-cause mortality. Compared with placebo, bemnifosbuvir treatment resulted in 0.61 log10 greater viral load mean change on day 2; trend sustained through day 8. Treatment-emergent adverse events were similar in both groups; most were mild/moderate, unrelated to study drug.
Conclusion:
Our results suggest a potential role for bemnifosbuvir in blunting COVID-19 progression.
Clinical Trial Registration:
NCT04396106 (ClinicalTrials.gov).
More Related Videos
05:46A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects
Published on: May 4, 2021
05:56Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases
Published on: January 9, 2019
